Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAL101 in Idiopathic Pulmonary Fibrosis
NCT06736990Phase 2Active, not recruiting
- Sponsor
- Calluna Pharma
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing CAL101 with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 28 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
idelalisib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06736990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736990.